[JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects].
作者信息
Håkansson Jan
机构信息
Krokoms hälsocentral,
出版信息
Lakartidningen. 2009;106(21-22):1460-1.
PMID:19579433
Abstract
摘要
相似文献
1
[JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects].
Lakartidningen. 2009;106(21-22):1460-1.
2
[JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].
Lakartidningen. 2009;106(21-22):1471-5.
3
[JUPITER study (2). For now no reason to give statins to more people].
Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):218-9.
4
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Am J Cardiol. 2006 Jan 16;97(2A):33A-41A. doi: 10.1016/j.amjcard.2005.11.014. Epub 2005 Dec 1.
5
[JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):216-7.
6
JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
Cardiovasc J Afr. 2009 May-Jun;20(3):211.
7
The editor's roundtable: the JUPITER trial--initial results and clinical implications.
Am J Cardiol. 2009 May 15;103(10):1417-25. doi: 10.1016/j.amjcard.2009.02.023.
8
The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Ther Adv Cardiovasc Dis. 2009 Aug;3(4):309-15. doi: 10.1177/1753944709337056. Epub 2009 May 21.
9
[JUPITER study, more reason to give statins as preventive measure - commentary].
Kardiol Pol. 2009 Mar;67(3):346-7.
10
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1038; author reply 1041-2. doi: 10.1056/NEJMc082574.
Zotero 插件